Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
$7.15M
Mr. Walter V. Klemp
13.00
Houston, TX
Jun 02, 2016
-0.21
$-11.73
1.89
2.39
-6,198.77%
-0.24
0.00
0.34
16.39
2.39
-98.40%
-100.16%
Similar stocks (13)
Capricor Therapeutics, Inc.
CAPR
PMV Pharmaceuticals, Inc.
PMVP
Anebulo Pharmaceuticals, Inc.
ANEB
NextCure, Inc.
NXTC
Akari Therapeutics, Plc
AKTX
AN2 Therapeutics, Inc.
ANTX
Inhibikase Therapeutics, Inc.
IKT
Pulmatrix, Inc.
PULM
Avenue Therapeutics, Inc.
ATXI
Allarity Therapeutics, Inc.
ALLR
Bio-Path Holdings, Inc.
BPTH
Cyclacel Pharmaceuticals, Inc.
CYCC
Panbela Therapeutics, Inc.
PBLA
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (13)
Capricor Therapeutics, Inc.
CAPR
PMV Pharmaceuticals, Inc.
PMVP
Anebulo Pharmaceuticals, Inc.
ANEB
NextCure, Inc.
NXTC
Akari Therapeutics, Plc
AKTX
AN2 Therapeutics, Inc.
ANTX
Inhibikase Therapeutics, Inc.
IKT
Pulmatrix, Inc.
PULM
Avenue Therapeutics, Inc.
ATXI
Allarity Therapeutics, Inc.
ALLR
Bio-Path Holdings, Inc.
BPTH
Cyclacel Pharmaceuticals, Inc.
CYCC
Panbela Therapeutics, Inc.
PBLA
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%